Factor V Leiden and prothrombin gene G20210A mutation and in vitro fertilization: prospective cohort study
Open Access
- 24 August 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 26 (11) , 3068-3077
Abstract
The influence of thrombophilia on fertility and on IVF outcome is very controversial. The objectives of this study were: (i) to compare the prevalence of Factor V Leiden (FVL) and prothrombin gene G20210A mutation (PGM) in women undergoing IVF to women with spontaneous pregnancy; (ii) to compare the IVF outcomes and the risk of complications in FVL and PGM carrier to non-carrier women. From March 2005 to December 2009, a total of 510 women requiring IVF were recruited in a prospective cohort study. A separate population of 490 nulliparous women who conceived naturally was also evaluated as fertile controls. All women were tested for the presence of FVL and PGM. The prevalence of thrombophilic mutations was the same among women requiring IVF (6.9%) and women with spontaneous pregnancy (6.9%). A total of 480 patients underwent 1105 IVF cycles. There were 30 women carriers (86 IVF cycles) and 450 non-carriers for thrombophilic mutations (1019 IVF cycles). No significant differences in the mean number of oocytes retrieved and the number of good quality embryos transferred were found between the mutation carrier and non-mutation carrier women; likewise the reproductive outcome and the IVF complications were not statistically different between the two groups. The cumulative live birth rate after six IVF cycles was similar in the mutation carrier and non-mutation carrier women. For the mutation carrier women, the optimistic estimate of cumulative live birth rate after six IVF cycles was 60.8% and the conservative estimate was 50.0%. Corresponding rates for the non-mutation carrier women were 56.8 and 36.2%, respectively. The results of this study suggest that FVL and PGM presence in asymptomatic women and in the absence of other risk factors do not influence IVF outcome, or represent risk factors for ovarian hyperstimulation syndrome (OHSS), or favour thrombosis after IVF. Screening for FVL and PGM does not appear to be justified to identify the patients at the risk for IVF failure, and/or for OHSS, and/or for thrombotic complications.Keywords
This publication has 51 references indexed in Scilit:
- The Association of Factor V Leiden and Prothrombin Gene Mutation and Placenta-Mediated Pregnancy Complications: A Systematic Review and Meta-analysis of Prospective Cohort StudiesPLOS Medicine, 2010
- The Truth About Inherited Thrombophilias and PregnancyObstetrics & Gynecology, 2010
- Prevalence of factor V Leiden and prothrombin G20210A mutation in a large French population selected for nonthrombotic history: geographical and age distributionBlood Coagulation & Fibrinolysis, 2009
- Is factor V Leiden mutation a cause of in vitro fertilization failure?Fertility and Sterility, 2009
- Unexplained infertility and inherited thrombophiliaFertility and Sterility, 2009
- Screening and treatment for heritable thrombophilia in pregnancy failure: inconsistencies among UK early pregnancy unitsBritish Journal of Haematology, 2008
- The prevalence of inherited thrombophilic polymorphisms in an asymptomatic Australian antenatal populationAustralian and New Zealand Journal of Obstetrics and Gynaecology, 2008
- ABO blood group, other risk factors and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE)Journal of Thrombosis and Haemostasis, 2007
- Artificial reproductive technology and the risk of venous thromboembolic diseaseJournal of Thrombosis and Haemostasis, 2006
- Internal jugular vein thrombosis after assisted conception therapyBritish Journal of Haematology, 2001